The Prognostic Value of Cardiopulmonary Exercise Testing Parameters in Patients With Coronary Heart Disease: A Retrospective Cohort Study(CPETPCAD) (CPET-PCHD)

April 9, 2026 updated by: Xiang Xie, Xinjiang Medical University

The Prognostic Value of Cardiopulmonary Exercise Testing Parameters in Patients With Coronary Heart Disease: A Retrospective Cohort Study

Parameters related to cardiopulmonary exercise testing (CPET) are important objective indicators for evaluating cardiopulmonary function in patients with coronary heart disease. However, the clinical application of CPET parameters in the prognostic assessment of patients with coronary heart disease remains unclear. This is a retrospective cohort study designed to systematically collect real-world clinical data and long-term follow-up outcomes of patients with coronary heart disease. Through standardized follow-up, this study will investigate the association between CPET parameters and adverse clinical outcomes in patients with coronary heart disease, as well as the relevant risk factors.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

15000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Non-Probability Sample

Study Population

Patients diagnosed with coronary heart disease in our hospital and who have completed cardiopulmonary exercise testing.

Description

Inclusion Criteria:

  1. Our hospital has diagnosed coronary heart disease and conducted cardiopulmonary exercise tests.
  2. Patients with complete clinical data.

Exclusion Criteria:

  1. Uncontrolled heart failure (NYHA classification Ⅲ-IV grade).
  2. Complications, such as moderate to severe anemia, tumors and lung diseases.
  3. Complicated with valvular heart disease.
  4. Unable to reach the anaerobic threshold during exercise.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Coronary Heart Disease Cohort

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cumulative incidence of Major Adverse Cardiovascular Events (MACE)
Time Frame: 1 year
The proportion of patients who experience an adjudicated Major Adverse Cardiovascular Event (MACE), defined as a composite endpoint consisting of non-fatal myocardial infarction, non-fata
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
All-cause mortality
Time Frame: 1 year
Record of deaths from any cause during follow-up. Confirmed by medical records, family follow-up, or national death registration systems.
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Xinjiang Medical University

Investigators

  • Study Chair: Xiang Xie, PhD, First Affiliated Hospital of Xinjiang Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 7, 2026

Primary Completion (Estimated)

January 31, 2027

Study Completion (Estimated)

June 30, 2027

Study Registration Dates

First Submitted

April 9, 2026

First Submitted That Met QC Criteria

April 9, 2026

First Posted (Actual)

April 16, 2026

Study Record Updates

Last Update Posted (Actual)

April 16, 2026

Last Update Submitted That Met QC Criteria

April 9, 2026

Last Verified

December 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • K202512-44

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Heart Disease (CHD)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Trinidad & Tobago

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe